This application for renewal of the UW/FHCRC CFAR includes the University of Washington, Fred Hutchinson Cancer Research Center, Seattle BioMed, and Seattle Children's Hospital, Foundation and Research Institute, and international partner institutions. Our CFAR has over 560 faculty, pre- and postdoctoral trainees, and research scientists. Matching financial support for our CFAR from partner institutions equals 35% of CFAR Direct Costs. The highly interdisciplinary CFAR membership represents 12 of the 16 UW Schools and Colleges and all five FHCRC Divisions. Annual external HIV/AIDS research, training, and service program funding to our four CFAR partners currently exceeds $362 million, including $160 million for 148 awards from six of seven CFAR co-sponsoring NIH institutes, OAR and the Fogarty Center. This warrants effective coordination and communication by the CFAR to optimize the return on investment. Strategic research priorities for the future are (1) Prevent New HIV Infections;(2) Improve HIV Disease Outcomes;(3) Expand Basic Science Discovery Research;and (4) Reduce HIV-Related Health Disparities. To achieve these aims, our goals are (1) Develop a New Generation of Young Innovative HIV/AIDS Researchers;and (2) Provide infrastructure, resources, and incentives for Sustainable Interdisciplinary Translational Science. Ten proposed Cores (three new or completely restructured) and three new Scientific Working Groups (SWGs) emphasize (1) Clinical, Epidemiology, Health Services, and Health Economics Research;(2) Socio- Behavioral and Prevention Research;and (3) Basic Discovery Research, including Retrovirology, Immunology, and Molecular Profiling/Computational Biology. Each Core has individual-level and population-level components, domestic and international components, and collaborations within and external to our CFAR. For the twenty-sixth year of the UW/FHCRC CFAR, we will continue to be innovative. A multi-stage Strategic planning process led to: (1) Merging current Clinical Research and Clinical Retrovirology Cores to improve efficiency and reduce costs;(2) Replacing the Computational Biology Core with a new Molecular Profiling and Computational Biology Core that synergizes FHCRC and UW strengths;(3) Creating an AIDS-Associated Infections and Malignancies Core from a successful SWG;and (4) Launching three new SWGs to build upon strong UW/FHCRC programs for research on Substance Abuse and HIV/STI;Implementation Science;and Curative Therapies for HIV. Cross-CFAR Cores (Administration, Developmental, Biometrics, and International) will support and interact with every Core. The CFAR will support and provide added value for future local, national and international HIV/AIDS research priorities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI027757-27S1
Application #
8910996
Study Section
Special Emphasis Panel (ZAI1-UKS-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2018-05-31
Budget Start
2014-08-15
Budget End
2015-05-31
Support Year
27
Fiscal Year
2014
Total Cost
$742,010
Indirect Cost
$170,479
Name
University of Washington
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Ross, Jennifer M; Ying, Roger; Celum, Connie L et al. (2018) Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. Epidemics 23:34-41
Patel, Rena C; Bukusi, Elizabeth A; Baeten, Jared M (2018) Current and future contraceptive options for women living with HIV. Expert Opin Pharmacother 19:1-12
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537
Wagner, Anjuli D; Shah, Seema K; Njuguna, Irene N et al. (2018) Financial Incentives to Motivate Pediatric HIV Testing-Assessing the Potential for Coercion, Inducement, and Voluntariness. J Acquir Immune Defic Syndr 78:e15-e18
Stekler, Joanne D; Violette, Lauren R; Niemann, Lisa et al. (2018) Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis. Open Forum Infect Dis 5:ofy197
Smith, Robert A; Wu, Vincent H; Zavala, Christopher G et al. (2018) In Vitro Antiviral Activity of Cabotegravir against HIV-2. Antimicrob Agents Chemother 62:
Katz, David A; Golden, Matthew R; Hughes, James P et al. (2018) HIV Self-Testing Increases HIV Testing Frequency in High-Risk Men Who Have Sex With Men: A Randomized Controlled Trial. J Acquir Immune Defic Syndr 78:505-512
Golob, Jonathan L; Stern, Joshua; Holte, Sarah et al. (2018) HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients. AIDS 32:2113-2118

Showing the most recent 10 out of 1275 publications